Indication
Mitochondrial DNA Deletion
1 clinical trial
2 products
Clinical trial
A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPowerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
PlaceboProduct
Elamipretide